Waters Corporation Introduces the ACQUITY SQD

UPLC/MS for Every Laboratory

For Immediate Release

Orlando, Florida, March 13, 2006 - Waters Corporation (NYSE: WAT) today introduced a new UPLC/MS system at the 57^th Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, March 12 – 17. The ACQUITY SQD puts the power of Ultra Performance Liquid Chromatography/Mass Spectrometry (UPLC^™/MS) into the hands of chromatographers.

The Waters^® ACQUITY^™ SQD gives scientists more information about the identity of pharmaceutical, biological, industrial and environmental compounds than conventional UV/Vis-based detector systems. LC/MS systems equipped with single quadrupole mass detectors have become increasingly popular for high-throughput LC/MS work in drug discovery and development laboratories due to the capability, affordability, usability and small footprint of the mass detector. Chromatographers can easily incorporate mass spectral data into routine analyses and provide increased confidence in their results.

This UPLC/MS system features the new Waters SQ Detector - a benchtop, ultra-compact, single-quadrupole, atmospheric pressure ionization (API) mass detector designed for routine UPLC/MS analyses. With first-of-its-kind IntelliStart^™ Diagnostic Software, the ACQUITY SQD tunes and calibrates the mass detector and conducts system performance checks allowing chromatographers to confidently acquire UPLC/MS data in routine analytical and open access applications.

Waters ACQUITY SQD applications include: peak purity/impurity profiling, synthesis confirmation, product deformulation, and enhanced methods development through the use of molecular weight-based peak tracking.

The Waters SQ Detector utilizes rapid scanning speeds of up to 10,000 amu/sec to deliver high quality mass spectral data in a compact package that is 40% smaller than its predecessor, the ZQ™ Mass Detector. The patented ZSpray^™ (dual orthogonal sampling) interface - the industry-leading source design for robust LC/MS - includes multi-mode ESCi^® ionization switching for atmospheric pressure chemical ionization (APCI) and electrospray (ESI) ionization in the same run, with rapid polarity switching for added productivity. Dedicated IonSABRE™ APCI and atmospheric pressure photo-ionization (APPI) probes are optional. System control and data acquisition are performed within Waters MassLynx™ 4.1 and Empower™ 2 software.

The mass range of the system extends to 2,000 Daltons and is the first complete LC/MS system to feature Waters Connections^® INSIGHT^™, an intelligent device diagnostic monitoring service that increases system uptime by securely collecting information about instrument conditions and then encrypting and transmitting it to secure proxy servers at Waters. In this way, preventive maintenance procedures can be performed before the scientist is even aware of the need for them.

Waters offers a full range of mass spectrometry options including single, tandem, time-of-flight, and quadrupole time-of-flight products for UPLC/MS and UPLC/MS/MS analyses.

About Waters Corporation

Waters Corporation holds worldwide leading positions in three complementary analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis. These market segments account for $4.5 - $5.0 billion of the overall $20+ billion analytical instrumentation market.

Waters, Connections and ESCi are registered trademarks and ACQUITY, Connections INSIGHT, Empower, IntelliStart, IonSABRE, MassLynx, ZQ and ZSpray are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

Certain statements contained herein are forward looking. Many factors could cause actual results to differ from these statements, including delays in product introductions, loss of market share through competition, introduction of competing products by other companies, pressures on prices from competitors and/or customers, regulatory obstacles to new product introductions, lack of acceptance of new products, changes in the healthcare market and the pharmaceutical industry, changes in distribution of the Company's products, and foreign exchange fluctuations. Such factors are discussed in detail in the Company's filings with the Securities and Exchange Commission and, in particular, the Company's Annual Report on Form 10-K for the year ended December 31, 2005.

Media Contact:
Contact: Brian J. Murphy
Corporate Communications
508-482-2614
brian_j_murphy@waters.com